Award
NIH Reporter #3R01AI184416-02S1
Therapeutic drug monitoring for linezolid in the treatment of rifampin-resistant tuberculosis: a pragmatic randomized controlled trial
Recipient
ALBERT EINSTEIN COLLEGE OF MEDICINE
Award Amount
$229,905.00
Ceiling
$229,905.00
Awarded
December 29, 2025
Identifier
3R01AI184416-02S1
A clinical trial funded by NIAID to assess therapeutic drug monitoring of linezolid in RR-TB patients to reduce toxicity and improve treatment outcomes.
Description
This project involves a clinical trial to evaluate the efficacy of therapeutic drug monitoring for linezolid in rifampin-resistant tuberculosis (RR-TB) patients, aiming to prevent toxicity and optimize treatment. The study will enroll 280 participants in South Africa, randomizing them to therapeutic drug monitoring or standard care, and compare rates of premature discontinuation and toxicity incidences.